Skip to main content

Table 1 Patient demographics, OAB characteristics, and baseline PROs

From: Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)

  Period 1 Total
  M/T
(n = 154)
T/M
(n = 144)
M/M
(n = 30)
T/T
(n = 30)
Mirabegrona
(n = 316)
Tolterodinea
(n = 310)
Women, n (%) 116 (75.3) 108 (75.0) 18 (60.0) 20 (66.7) 232 (73.4) 233 (75.2)
Mean (SD) age, years 53.5 (14.8) 52.3 (12.6) 59.0 (13.1) 54.9 (14.8) 53.4 (13.9) 53.2 (13.7)
Age group, n (%)
  < 65 years 117 (76.0) 120 (83.3) 20 (66.7) 21 (70.0) 247 (78.2) 243 (78.4)
  ≥ 65 years 37 (24.0) 24 (16.7) 10 (33.3) 9 (30.0) 69 (21.8) 67 (21.6)
Race, n (%)
 White 123 (79.9) 116 (80.6) 24 (80.0) 24 (80.0) 253 (80.1) 248 (80.0)
 Black/African American 28 (18.2) 23 (16.0) 4 (13.3) 5 (16.7) 53 (16.8) 53 (17.1)
 Asian 2 (1.3) 4 (2.8) 1 (3.3) 1 (3.3) 7 (2.2) 7 (2.3)
 American Indian/Alaska native 0 1 (0.7) 0 0 1 (0.3) 1 (0.3)
 Other 1 (0.6) 0 1 (3.3) 0 2 (0.6) 1 (0.3)
Ethnicity, n (%)
 Hispanic/Latino 33 (21.4) 24 (16.7) 8 (26.7) 6 (20.0) 65 (20.6) 61 (19.7)
 Not Hispanic/Latino 121 (78.6) 120 (83.3) 22 (73.3) 24 (80.0) 251 (79.4) 249 (80.3)
Mean (SD) BMI (kg/m2) 28.75 (6.65) 29.96 (7.10) 31.25 (8.49) 31.64 (10.98) 29.56 (7.08) 29.70 (7.45)
OAB characteristics N = 154 N = 144 N = 30 N = 30 N = 341 N = 336
Mean duration of OAB, months (SD) 81.85 (74.34) 75.11 (99.13) 74.06 (84.98) 67.16 (59.96) 76.98 (86.66) 77.57 (84.62)
Type of OAB, n (%)
 Urgency incontinence only 65 (42.2) 55 (38.2) 12 (40.0) 14 (46.7) 139 (40.8) 140 (41.7)
 Mixed stress/Urgency incontinence with urgency as predominant factor 53 (34.4) 50 (34.7) 10 (33.3) 8 (26.7) 116 (34.0) 112 (33.3)
 Frequency/urgency without incontinence 36 (23.4) 39 (27.1) 8 (26.7) 8 (26.7) 86 (25.2) 84 (25.0)
Incontinent patients at baseline of Period 1, n (%)
 Wet 117 (76.0) 98 (68.1) 24 (80.0) 22 (73.3) 250 (73.3) 241 (71.7)
 Dry 37 (24.0) 46 (31.9) 6 (20.0) 8 (26.7) 91 (26.7) 95 (28.3)
Previous non-drug treatment, n (%)
 Yes 6 (3.9) 6 (4.2) 1 (3.3) 3 (10.0) 11 (3.2) 17 (5.1)
 No 148 (96.1) 138 (95.8) 29 (96.7) 27 (90.0) 330 (96.8) 319 (94.9)
Baseline PROs N = 154 N = 144 N = 30 N = 30 N = 337 N = 336
Premedication OAB-S scales, mean (SE)
 Impact on Daily Living with OAB 44.71 (2.37) 48.36 (2.38)
[n = 143]
40.50 (5.50) 47.33 (5.15) 51.49 (1.67) 53.78 (1.60)
[n = 335]
 Overall Assessment of Interruption of Day-to-Day Life Due to OAB 1.69 (0.07) 1.67 (0.07)
[n = 143]
1.57 (0.14) 1.77 (0.19) 1.95 (0.06) 2.01 (0.06)
[n = 335]
OAB-q scales and PPBC, mean (SE)
 Symptom Bother (0–100; higher score indicates greater bother) 61.20 (1.65) 60.83 (1.62) 66.83 (3.79) 59.83 (3.94) 52.67 (1.28) 51.14 (1.28)
 Coping (0–100; higher score indicates improvement) 48.04 (2.25) 51.89 (2.23) 47.50 (6.01) 53.58 (4.58) 56.98 (1.59) 59.96 (1.52)
 Concern (0–100; higher score indicates improvement) 51.54 (1.97) 51.57 (2.04) 50.86 (4.74) 56.67 (4.30) 59.86 (1.42) 61.60 (1.41)
 Sleep (0–100; higher score indicates improvement) 40.99 (2.13) 44.53 (2.23) 37.20 (4.63) 48.53 (5.27) 51.09 (1.59) 52.44 (1.54)
 Social Interaction (0–100; higher score indicates improvement) 75.45 (2.05) 77.44 (2.00) 70.00 (4.71) 76.53 (4.41) 78.86 (1.33) 80.54 (1.28)
 HRQL total (0–100; higher score indicates better QoL) 53.09 (1.83) 55.44 (1.88) 50.88 (4.69) 58.03 (4.15) 60.99 (1.34) 63.03 (1.31)
 PPBC (1–6; higher score indicates deterioration in bladder condition) 4.51 (0.08) 4.54 (0.09)
[n = 143]
4.47 (0.21) 4.40 (0.15) 4.20 (0.06) 4.16 (0.06)
[n = 335]
  1. a Patients with the same treatment in two different periods (sequences M/M and T/T) are counted once